MedPath

Comparison of the Effectiveness of dexmedetomidine and propofol in electrochemotherapy of breast cancer skin lesio

Phase 2
Recruiting
Conditions
breast cancer skin lesion.
Secondary malignant neoplasm of skin
C79.2
Registration Number
IRCT20240515061805N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
36
Inclusion Criteria

Symptomatic metastatic skin lesions (like bleeding, exudation, smell or ulceration)
development of skin metastases, in which the symptoms mentioned can be expected
Patients who receive systemic treatment and have a good effect on their primary cancer, but their skin lesions do not respond to these treatments or are progressing
patients preferring electrochemistry
multiple skin lesions or a lesion larger than 1 cm
ASA group II, I, III
patients between 18 and 60 years old

Exclusion Criteria

Pregnancy and breastfeeding
Allergy to any of the drugs used in the study
hypertension
impaired liver and kidney function
Hereditary heart diseases
ischemic heart disease,
smoking
using beta blockers and sedative drugs
refusing to sign an informed consent form

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.